Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.65Wanbury Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by high return on capital employed and return on assets. Growth is supported by significant increases in operating profit and assets. However, the company faces challenges in liquidity, efficiency, and certain financial metrics, particularly related to earnings per share and revenue growth. Coverage ratios are moderate, indicating an ability to meet interest obligations but a lack of dividend coverage. Overall, Wanbury Ltd exhibits potential for sustained profitability and asset expansion, but needs to address its liquidity and efficiency to ensure long-term financial stability.
Health Score : 4.65Wanbury Ltd, operating in the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and profitability, driven by high return on capital employed and return on assets. Growth is supported by significant increases in operating profit and assets. However, the company faces challenges in liquidity, efficiency, and certain financial metrics, particularly related to earnings per share and revenue growth. Coverage ratios are moderate, indicating an ability to meet interest obligations but a lack of dividend coverage. Overall, Wanbury Ltd exhibits potential for sustained profitability and asset expansion, but needs to address its liquidity and efficiency to ensure long-term financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
15.92
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
27.30
P/B RATIO
14.06
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
N/A
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹254.4 as on Sep 1, 2026.
Growth Score : 4.00The growth metrics indicate a mixed performance. While the company shows significant growth in operating profit and assets, revenue and net income growth rates are low. There is a need to improve revenue generation to ensure balanced and sustainable growth across all key areas.
Revenue Growth RatePoor
Operating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 6.81 | 30.36 | -5.09 | 14.85 | 7.72 |
| Operating Profit Growth Rate | -21.74 | 100 | -27.78 | 180.77 | 9.59 |
| Earnings Per Share (EPS) Growth | -119.54 | 594.84 | -112.75 | 637.42 | -45.47 |
| Asset Growth Rate | 3.58 | 22.15 | -13.88 | 12.83 | 20.7 |
| Net Income Growth Rate | -120.31 | 723.08 | -112.35 | 660 | -44.64 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 22.25 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 10 | Infinium Pharmachem Ltd | 6.42 | 33.97 | Neutral | 22.00 | 6.43 | 14.00 |
| 11 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 12 | Albert David Ltd | 5.63 | -333.98 | Neutral | 5.00 | -2.62 | -1.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -0.80 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Wanbury Ltd. is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs). It caters to various therapeutic segments, including anti-diabetic, cardiovascular, gastro-intestinal, and pain management, serving both domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Wanbury Ltd's P/E ratio (TTM) is 15.92, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Wanbury Ltd's P/B ratio is 14.06, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Wanbury Ltd's P/S ratio is 1.02, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Wanbury Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Wanbury Ltd's EV/EBITDA ratio is 18.28.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Wanbury Ltd's ROE is 52.54%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Wanbury Ltd's ROA is 19.32%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Wanbury Ltd's ROCE is 37%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Wanbury Ltd's operating margin is 13.33%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Wanbury Ltd's net margin is 5.17%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Wanbury Ltd's current ratio is 1.10.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Wanbury Ltd's debt-to-equity ratio is 2.85.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Wanbury Ltd's interest coverage ratio is 1.81.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Wanbury Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Wanbury Ltd's EPS is -45.47.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹254.40. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1990
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDFs), Nutraceuticals
Stock Listing: NSE (WANBURY), BSE (524212)
Promoter: Dr. V.M. Naik & Group
Wanbury Limited was incorporated in 1990. The company steadily built its presence in the Indian pharmaceutical market, focusing on both API and FDF segments. A notable expansion occurred in 2006 with the acquisition of Laboratories del Dr. Esteve, S.A., Spain, which was later divested. In recent years, Wanbury has focused on strengthening its manufacturing capabilities and product portfolio across various therapeutic areas in both domestic and international markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Finished Formulations | 66.7% | Operating Profit |
| Active Pharmaceutical Ingredients (API) | 33.3% | Operating Profit |
Finished Formulations: Engaged in the development, manufacturing, and marketing of a wide range of finished dosage forms, targeting therapeutic areas like anti-diabetic, cardiovascular, gastro-intestinal, and pain management. Products are sold in both domestic and international markets.
Active Pharmaceutical Ingredients (API): Focuses on the production of bulk drugs (APIs) used for captive consumption in formulations and supplied to other pharmaceutical manufacturers, covering various therapeutic segments.
Dr. V.M. Naik - Chairman & Managing Director. A visionary leader with extensive experience in the pharmaceutical industry, he has guided Wanbury since its inception. Ms. Bhavna V. Naik - Joint Managing Director.
In September 2023, the company completed a Rights Issue of 2,49,99,999 equity shares at ₹75 per share, aggregating to ₹187.50 crores.
The Wanbury Ltd share price today is ₹254.40 on NSE (WANBURY), as of 26 Sept 2026.
As of 25 Sept 2026, Wanbury Ltd share price is ₹254.40, with previous close ₹254.40. Today's range is ₹254.40 to ₹254.40. The 52-week range is ₹161.50 to ₹358.85.
As of today, Wanbury Ltd's market cap is ₹0 crore (Small Cap).
Wanbury Ltd's current P/E ratio is 15.92, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 35.
Wanbury Ltd's current P/B ratio is 14.06.
Wanbury Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Wanbury Ltd's EPS (TTM) is ₹-45.47.
Wanbury Ltd. is an Indian pharmaceutical company primarily engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations (FDFs). It caters to various therapeutic segments, including anti-diabetic, cardiovascular, gastro-intestinal, and pain management, serving both domestic and international markets.
Wanbury Ltd is promoted by Dr. V.M. Naik & Group, holding 43.02% as of 25 Sept 2026.
Wanbury Ltd is listed on NSE (WANBURY) and BSE (524212). Its next quarterly results are expected on August 2024.
Cash Earnings Per Share (Cash EPS)
